BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16115720)

  • 1. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
    Maniratanachote R; Shibata A; Kaneko S; Yamamori I; Wakasugi T; Sawazaki T; Katoh K; Tokudome S; Nakajima M; Yokoi T
    Toxicology; 2005 Dec; 216(1):15-23. PubMed ID: 16115720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone.
    Yokoi T
    Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
    Watanabe I; Tomita A; Shimizu M; Sugawara M; Yasumo H; Koishi R; Takahashi T; Miyoshi K; Nakamura K; Izumi T; Matsushita Y; Furukawa H; Haruyama H; Koga T
    Clin Pharmacol Ther; 2003 May; 73(5):435-55. PubMed ID: 12732844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody to aldolase in acute and chronic hepatitis.
    Brown C; Toh BH; Pedersen JS; Clarke FM; Mackay IR; Gust I
    Pathology; 1987 Oct; 19(4):347-50. PubMed ID: 3328140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an anti-aldolase autoantibody as a diagnostic marker for diabetic retinopathy by immunoproteomic analysis.
    Ahn BY; Song ES; Cho YJ; Kwon OW; Kim JK; Lee NG
    Proteomics; 2006 Feb; 6(4):1200-9. PubMed ID: 16421937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
    Caldwell SH; Hespenheide EE; von Borstel RW
    Dig Dis Sci; 2001 Feb; 46(2):376-8. PubMed ID: 11281188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
    Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
    Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rules and laws of drug hepatotoxicity.
    Kaplowitz N
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791
    [No Abstract]   [Full Text] [Related]  

  • 10. Second-generation thiazolidinediones and hepatotoxicity.
    Marcy TR; Britton ML; Blevins SM
    Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinedione hepatotoxicity: a class effect?
    Tolman KG
    Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel antidiabetic drug, troglitazone--reason for hope and concern.
    Imura H
    N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
    [No Abstract]   [Full Text] [Related]  

  • 13. An autopsy case of troglitazone-induced fulminant hepatitis.
    Shibuya A; Watanabe M; Fujita Y; Saigenji K; Kuwao S; Takahashi H; Takeuchi H
    Diabetes Care; 1998 Dec; 21(12):2140-3. PubMed ID: 9839107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal hepatotoxicity associated with troglitazone.
    Vella A; de Groen PC; Dinneen SF
    Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
    [No Abstract]   [Full Text] [Related]  

  • 15. Troglitazone (Rezulin) and hepatic injury.
    Faich GA; Moseley RH
    Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
    Li H; Heller DS; Leevy CB; Zierer KG; Klein KM
    J Diabetes Complications; 2000; 14(3):175-7. PubMed ID: 10989325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
    Menon KVN ; Angulo P; Lindor KD
    Am J Gastroenterol; 2001 May; 96(5):1631-4. PubMed ID: 11374713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effect and side effect of troglitazone].
    Toyota T; Ueno Y
    Nihon Rinsho; 2000 Feb; 58(2):376-82. PubMed ID: 10707561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
    Graham DJ; Drinkard CR; Shatin D
    Am J Gastroenterol; 2003 Jan; 98(1):175-9. PubMed ID: 12526954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
    Fukano M; Amano S; Sato J; Yamamoto K; Adachi H; Okabe H; Fujiyama Y; Bamba T
    Hum Pathol; 2000 Feb; 31(2):250-3. PubMed ID: 10685643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.